dr. ezra cohen discusses the cabozantinib dose size and tolerability
Published 11 years ago • 352 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
0:59
dr. ezra cohen discusses the cabozantinib exam trial
-
1:27
dr. ezra cohen on the efficacy and pharmacokinetics of cabozantinib
-
2:06
dr. ezra cohen discusses treating medullary thyroid cancer
-
1:59
dr. cohen discusses promise of immunotherapy in head and neck cancer
-
1:43
dr. cohen on the quality of life in head and neck cancer
-
1:15
dr. cohen on mtor inhibition in head and neck cancer
-
1:36
dr. cohen on immunotherapeutic advances in head and neck cancer
-
1:34
dr. vogelzang discusses the cabozantinib trial design
-
3:51
checkpoint inhibitors in hnscc
-
2:42
dr. cohen on the rationale of the active8 study in scchn
-
1:34
dr. eric sherman on the sequencing of cabozantinib and vandetanib for mtc
-
1:14
dr. vogelzang describes cabozantinib's side effects
-
47:05
immunotherapy in head and neck cancer: prof. ezra cohen
-
2:07
dr. cohen on challenges with immunotherapy in head and neck cancer
-
1:36
dr. vogelzang discusses mortalities in cabozantinib trial
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
5:56
the rationale for cabozantinib in advanced rcc
-
2:45
sequencing with cabozantinib in advanced hcc
-
0:52
dr. choueiri on the role of cabozantinib in rcc